Agendia Will Present AI Cancer Research in October
The company will debut digital pathology findings at the ESMO Congress 2026 in Madrid.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you trust artificial intelligence to provide accurate diagnostic information for serious medical conditions?
On October 24, 2026, Agendia will showcase new research regarding an AI-driven digital pathology approach for breast cancer analysis. The presentation is scheduled to take place at the upcoming ESMO Congress in Madrid.
Why it matters
AI-driven digital pathology is being developed to potentially expand global access to precise genomic testing. This technology aims to streamline the evaluation of routine tissue slides for patients with breast cancer.
The FLEX Study platform has enrolled 25,000 patients, while the MammaPrint test assesses risk using 70 genes and the BluePrint assay utilizes an 80-gene molecular subtyping panel. Research includes 2,981 invasive lobular carcinoma tumors.
The players
Agendia
This molecular diagnostics company operates out of Amsterdam and Irvine and specializes in breast cancer genomic testing.
ESMO Congress 2026
This major international oncology gathering hosts researchers and clinicians to share advancements in cancer treatment and diagnostics.
The details
The AI platform analyzes routine whole slide images of breast cancer tissue to assist in prognosis. Agendia will supplement this podium presentation with two additional research posters during the five-day congress.
Timeline
The ESMO Congress 2026 takes place from October 23 to 27, 2026.
The AI-driven digital pathology podium presentation is set for October 24, 2026.
The Big Picture
The research on AI pathology follows data patterns established by the FLEX Study regarding diverse patient enrollment and genomic profiling. This approach underscores the transition toward integrating digital image analysis with existing molecular diagnostic platforms.
This research may eventually expand access to high-quality genomic risk assessment for breast cancer patients regardless of their location. Such diagnostic tools are intended to help clinicians make more informed treatment decisions based on molecular data.
The takeaway
Advancements in AI-driven digital pathology could bridge the gap between traditional histology and precision genomic medicine. These tools represent a shift toward utilizing existing clinical data to improve patient diagnostic experiences.
Further reading
For more information on current developments in oncology, visit the Cancer section.
Source note: This article includes information reported by AFP.
Live Poll
Do you trust artificial intelligence to provide accurate diagnostic information for serious medical conditions?
